[1] Buyse, M. (1991) Cyclophosphamide plus cisplatin versus cyclophosphomide, doxorubicin, and cisplatin chemotherapy of ovarian-carcinoma-ameta-analysis. Journal of Clinical Oncology, 9 (9), 1668-74.

[2] McGuire, W.P., Hoskins, W.J., Brady, M.F., Kucera, P.R., Partridge, E.E., Look, K.Y., Clarke Pearson, D.L., and Davidson, M. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal ofMedicine, 334(1), 1-6.

[3] Muggia, F.M., Braly, P.S., Brady, M.F., Sutton, G., Niemann, T.H., Lentz, S.L., Alvarez, R.D., Kucera, P.R., and Small, J.M. (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 18(1), 106-15.

[4] The International Collaborative Ovarian Neoplasm (ICON) Group. (2002) Paclitaxel plus carbo-platin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 360, 505-15.

[5] TheICON2 Collaborators. (1998) Randomized trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet, 352(9140), 1571-6.

[6] Schwartz, F., and Lellouch, A. (1967) Explanatory and pragmatic attitudes in therapeutic trials. Journal of Chronic Diseases, 20, 637-48.

[7] Stenning, S.P. (1992) Selection of patients for cancer clinical trials - the uncertainty principle. In Introducing New Treatments for Cancer (ed. C.J. Williams). pp. 161-72, Wiley, New York.

[8] Freedman, B. (1987) Equipoise and the ethics of clinical research. New England Journal of Medicine, 317, 141-5.

[9] International Collaboration of Trialists. (1999) Adjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. Lancet, 354(9178), 533-40.

[10] Zelen, M. (1979) A new design for randomized clinical trials. New England Journal of Medicine, pp. 1242-5.

[11] Krongborg, O., Fenger, C., Olsen, J., Jorgensen, O.D., and S0ndergaard, O. (1996) Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet, 348, 1467-71.

[12] Olschewski, M., and Scheurlen, H. (1985) Comprehensive cohort study: An alternative to randomized consent design in a breast preservation trial. Methods of Information in Medicine, 24, 131-4.

[13] Altman, D.F., Whitehead, J., Parmar, M.K.B., Stenning, S.P., Fayers, P.M., and Machin, D. (1995) Randomized consent designs in cancer clinical trials. European Journal of Cancer, 31A, 1934-44.

[14] Alexander, F.E., Anderson, T.J., Brown, H.K., Forrest, A.P.M., Hepburn, W., Kirkpatrick, A.E., McDonald, C., Muir, B.B., Prescott, R.J., Shepherd, S.M., Smith, A., and Warner, J. (1994) The Edinburgh randomized trial of breast cancer screening: results after 10 years of follow-up. British Journal ofCancer, 70, 542-8.

[15] Moher, M., Yudkin, P., Wright, L., Turner, R., Fuller, A., Schofield, T., and Mant, D. (2001) Cluster randomized controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. British Medical Journal, 322(7298), 1338-42.

[16] Hutton, J. (2001) Are distinct ethical principles required for cluster randomized controlled trials? Statistics in Medicine, 20, 473-88.

[17] Donner, A. (1998) Some aspects of the design and analysis of cluster randomized trials. Applied Statistics, 47 (1), 95-113.

[18] Elbourne, D.R., and Campbell, M.K. (2001) Extending the CONSORT statement to cluster randomized trials: for discussion. Statistics in Medicine, 20, 489-96.

[19] Medical Research Council. (1984) The evaluation of low-dose pre-operative X-ray therapy in the management of operable rectal cancer; results of a randomly controlled trial. British Journal of Surgery, 71, 21-5.

[20] Seymour, M. on behalf on the MRC Colorectal Cancer Group and all the participants. (2001) An update on the MRC FOCUS/CR08 trial: the first 300 patients. British Journal of Cancer, 85 (suppl 1), 44 (absP.45).

[21] Karim, A.B.M.F., Maat, B., Hatlevoll, R., Menten, J., Rutten, E.H.J.M., Thomas, D.G.T, Mascarenhas, F., Horiot, J.C., Parvinen, L.M., vanReijn, M., Hamers, H.P., Gaspar, L., Noord-man, E., Pierart, M., vanGlabbeke, M., vanAlphen, A.M., Jager, J.J., and Fabrini, M.G. (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. International Journal of Radiation Oncology Biology Physics, 36 (3), 549-56.

[22] Karim, A.B.M.F., Afra, D., Cornu, P., Bleehen, N., Schraub, S., De Witte, O., Darcel, F., Stenning, S., Pierart, M., and Van Glabbeke, M. (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: An interim analysis. International Journal of Radiation Oncology Biology Physics, 52(2), 316-24.

[23] Gray, R., James, R., Mossman, J., and Stenning, S.P. (1991) Guest editorial: AXIS - A suitable case for treatment. British Journal of Cancer, 63, 841-5.

[24] Bruera, E., Belzile, M., Pituskin, E., Fainsinger, R., Darke, A., Harsanyi, Z., Babul, N., and Ford, I. (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Journal of Clinical Oncology, 16(10), 3222-9.

[25] Hills, M., andArmitage, P. (1979) The two-period cross-over clinical trial. British Journal of Clinical Pharmacology, 8, 7-20.

[26] Senn, S. (1993) Cross-over Trials in Clinical Research. John Wiley, Chichester.

[27] Maughan, T.S., James, R.D., Kerr, D.J., Ledermann, J.A., McArdle, C., Seymour, M.T., Cohen, D., Hopwood, P., Johnston, C., and Stephens, R.J. For the British MRC Colorectal Cancer Working Party. (2002) Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomized trial. Lancet, 359, 1555-63.

[28] Pocock, S.J., and Simon, R. (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics, 31, 103-15.

[29] Parmar, M.K.B., Griffiths, G.O., Spiegelhalter, D.J., Souhami, R.L., Altman, D.G., and van der Scheuren, E. (2001) Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet, 358(9279), 375-81.

[30] Hill, L.E., Nunn, A., and Fox, W. (1976) Matching quality of agents employed in 'double blind' controlled clinical trials, Lancet, I, 352-56.

[31] Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90, 1371-88.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment